Nirmatrelvir-ritonavir (Paxlovid) Access, Use, and Eligibility Among Adults with COVID-19 in Los Angeles County: The LA Pandemic Surveillance Cohort Study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      COVID-19 treatment; COVID-19; ADULTS; COHORT analysis; PANDEMICS; ETHNIC differences
    • Subject Terms:
      LOS Angeles (Calif.)
    • Abstract:
      This document summarizes a study on the use of the COVID-19 treatment drug, Nirmatrelvir-ritonavir (Paxlovid), among adults in Los Angeles County. The study found that a relatively low percentage of eligible patients received prescriptions for the drug during a specific time period. The research aimed to determine if there were any disparities in access to the drug based on demographics or socioeconomic factors. The results showed that while there were no significant differences in access based on eligibility, older adults had higher odds of using the drug. The study also noted that disparities in access may arise now that the drug is no longer free. [Extracted from the article]
    • Abstract:
      Copyright of JGIM: Journal of General Internal Medicine is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)